- Monguió-Tortajada, Marta|||0000-0003-2125-0810
- Prat-Vidal, Cristina|||0000-0002-5621-1101
- Martínez-Falguera, Daina|||0000-0002-9439-0542
- Teis, Albert|||0000-0002-4820-0736
- Soler-Botija, Carolina|||0000-0002-4584-9134
- Courageux, Yvan|||0000-0002-1484-2677
- Munizaga-Larroudé, Micaela
- Font-Morón, Miriam|||0000-0002-4714-252X
- Bayés-Genís, Antoni|||0000-0002-3044-197X
- Borràs i Serres, Francesc Enric|||0000-0003-4038-1912
- Rudilla, F..
- Gálvez-Montón, Carolina|||0000-0003-2254-9371
Rationale: Extracellular vesicles (EVs) from mesenchymal stromal cell (MSC) are a potential therapy for cardiac healing after myocardial infarction (MI). Nevertheless, neither their efficient administration nor therapeutic mechanisms are fully elucidated. Here, we evaluate the preclinical efficacy of a tissue engineering approach to locally deliver porcine cardiac adipose tissue MSC-EV (cATMSC-EV) in an acute MI pig model. Methods: After MI by permanent ligation of the coronary artery, pigs (n = 24) were randomized to Untreated or treated groups with a decellularised pericardial scaffold filled with peptide hydrogel and cATMSC-EV purified by size exclusion chromatography (EV-Treated group) or buffer (Control group), placed over the post-infarcted myocardium. Results: After 30 days, cardiac MRI showed an improved cardiac function in EV-Treated animals, with significantly higher right ventricle ejection fraction (+20.8% in EV-Treated; p = 0.026), and less ventricle dilatation, indicating less myocardial remodelling. Scar size was reduced, with less fibrosis in the distal myocardium (-42.6% Col I in EV-Treated vs Untreated; p = 0.03), a 2-fold increase in vascular density (EV-Treated; p = 0.019) and less CCL2 transcription in the infarct core. EV-treated animals had less macrophage infiltration in the infarct core (-31.7% of CD163 + cells/field in EV-Treated; p = 0.026), but 5.8 times more expressing anti-inflammatory CD73 (p = 0.015). Systemically, locally delivered cATMSC-EV also triggered a systemic effect, doubling the circulating IL-1ra (p = 0.01), and reducing the PBMC rush 2d post-MI, the TNFα and GM-CSF levels at 30d post-MI, and modulating the CD73 + and CCR2 + monocyte populations, related to immunomodulation and fibrosis modulation. Conclusions: These results highlight the potential of cATMSC-EV in modulating hallmarks of ischemic injury for cardiac repair after MI.
Project:
Fundació la Marató de TV3 / 201516-10
,
Agencia Estatal de Investigación / PID-2019-110137RB-I00
,
Agencia Estatal de Investigación / SAF2017-84324-C2-1-R
,
Instituto de Salud Carlos III / PI18/00256
,
Instituto de Salud Carlos III / ICI19/00039
,
Instituto de Salud Carlos III / ICI20/00135
,
Ministerio de Economía y Competitividad / RD16/0011/0006
,
Ministerio de Economía y Competitividad / CB16/11/00403
,
Instituto de Salud Carlos III / PI21/01703
,
Agència de Gestió d'Ajuts Universitaris i de Recerca / 2017/SGR-483
,
Agència de Gestió d'Ajuts Universitaris i de Recerca / 2017/SGR-301